Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

REGN Regeneron Pharmaceuticals Inc

700,33

4,31 (0,62%)

21 Fev 2025 - Fechado

Atrasado em 15 minutos

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Regeneron Pharmaceuticals.

Notícias Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN
Quinta, 20 de Fevereiro de 2025 (2 dias atrás) • PR Newswire (US)

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
Terça, 18 de Fevereiro de 2025 (4 dias atrás) • GlobeNewswire Inc.

The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
Quinta, 13 de Fevereiro de 2025 (1 semana atrás) • PR Newswire (US)

Regeneron Announces Investor Conference Presentations
Terça, 11 de Fevereiro de 2025 (1 semana atrás) • GlobeNewswire Inc.

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Terça, 11 de Fevereiro de 2025 (2 semanas atrás) • GlobeNewswire Inc.

The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
Segunda, 10 de Fevereiro de 2025 (2 semanas atrás) • PR Newswire (US)

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
Sábado, 8 de Fevereiro de 2025 (2 semanas atrás) • GlobeNewswire Inc.

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
Sábado, 8 de Fevereiro de 2025 (2 semanas atrás) • GlobeNewswire Inc.

Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Sexta, 7 de Fevereiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact The Gross Law Firm
Quinta, 6 de Fevereiro de 2025 (2 semanas atrás) • PR Newswire (US)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Quarta, 5 de Fevereiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Terça, 4 de Fevereiro de 2025 (3 semanas atrás) • Edgar (US Regulatory)

Mais Notícias de Regeneron Pharmaceuticals Inc

LOJAS RENNER ON

Índice Bovespa

PÃO DE AÇUCAR ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições